

Measuring Patient Outcomes from Cancer Across GM


Dr John Moore*, Lisa Galligan-Dawson^, Dr Jenna Lane^ on behalf of the GM Cancer Clinical Outcomes and Data Group&

*Manchester University NHS Foundation Trust and GM Cancer Alliance, ^GM Cancer Alliance.

Context

Currently, it is extremely challenging to understand GM patient outcomes from cancer, due to lack of system-wide consensus on key outcomes to measure and appropriate data to support the work.

GM currently depends on limited information from NHS England, e.g. cancer stage and survival. With a 2-3-year time lag, this has limited value for rapid feedback on the effects of improvement projects.



1-year survival for breast, lung and colorectal cancer for GM. Data provided by NHS England for patients diagnosed in 2020.

GM is breaking new ground as the first cancer alliance in the UK to take charge of measuring its own cancer outcomes, which will inform targeted improvement work in the future.

Roadmap for clinical outcomes

Initial scoping work has laid the ground for the next 1-2 years of exploratory work:

- Establish core and pathway-specific outcome metrics for GM
- Gain timely access to the required (pseudonymised) patient-level data at system level
- Facilitate collaboration with the Christie Clinical Outcomes and Data Unit on system-wide projects relating to patient outcomes
- Embed the consideration of health economics and patient outcomes in GM Cancer projects
- Targeted cancer interventions based on population health data.

System-wide consultation

During 2023 a GM-wide consultation was undertaken with cancer pathway boards, patient forums and Cancer Alliance programme leads to gain a holistic understanding of which outcomes are most important to GM as a cancer system.

It was agreed that the following would be measured initially, with a view to extending once these metrics have been established:

- Patient survival (1,2,3,5,10+ years)
 - Stage of presentation
 - Quality of life


Patient perspectives

Patient groups particularly highlighted the importance of understanding harms caused by treatments, e.g. the long-term effects of radiotherapy. Patients were also keen to understand cancer survival by pathway beyond 10 years.

Health economics

Health economics is becoming an increasingly important tool to assess and demonstrate the benefits of projects and influence decision-making around funding.

Worked collaboratively with York Health Economics Consortium to develop a Framework for Health Economic Evaluation.



- Simple checklist and flow chart
- Designed to support project teams with upfront consideration of the expected costs and benefits at the outset of a project.

In parallel developing a collaboration with Astra Zeneca around detailed health economic analysis of GM Cancer projects and pathways.

Health inequalities

Addressing health inequalities underpins the entirety of the work around GM cancer clinical outcomes.

Efforts to access better data on patient outcomes and maximise effective use of this data will provide GM with new insights into where health inequalities exist in our system in relation to cancer, namely:

- Identifying inequalities in patient outcomes will allow targeted interventions to be designed.
- A shorter time lag on data around patient outcomes will allow rapid feedback on the effects of improvement projects on health inequalities and inform future directions.
- Use of the Framework for Health Economic Evaluation will support the assessment of impact of projects on patient outcomes.

Next steps

- Establish the required data flows to underpin system-wide understanding of patient outcomes from cancer.
- Launch the GM Cancer Framework for Health Economic Evaluation.
- Further develop collaboration with Astra Zeneca around health economic analysis of GM Cancer projects and pathways.